Olema Pharmaceuticals, Inc. (OLMA) Form SCHEDULE 13D/A — Oct 16, 2026
The BVF investment group led by Mark Lampert filed Amendment No. 4 to its Schedule 13D on Olema Pharmaceuticals, restating beneficial ownership at approximately 9.8% of shares outstanding (8,939,731 shares including pre-funded warrants), held across BVF, BVF2 and related entities. The amendment discloses that Dr. Gorjan Hrustanovic, a BVF-affiliated board member, resigned from Olema's board and its Compensation and Science & Technology Committees effective October 14, 2026, with the filing stating the resignation was not the result of any disagreement with the company.
Key figures
- Bvf shares
- 5946981
- Bvf2 shares
- 2356800
- Bvf percent
- 6.6%
- Bvf2 percent
- 2.7%
- Hrustanovic option shares
- 183645
- Partners aggregate shares
- 8939731
- Partners aggregate percent
- 9.8%
- Blocker exercise limit shares
- 3643838
- Shares outstanding denominator
- 87497607
- Pre funded warrants underlying shares
- 6373040
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.